Home

MICHAEL GRAY

CIK 1271411 · CFO and COO · last filed 2026-06-17

MICHAEL GRAY is a CFO and COO who has filed 29 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing shows the insider sold $5.2K of UPB on Jun 17, 2026. Across all open-market trades the lifetime net is −$402.9K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $173.1K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$173.1K

Companies

4

Total Filings

29

Lifetime Open-Market Net

-$402.9K

Filer Profile

Reported Address
C/O CURIS INC
4 MAGUIRE ROAD
LEXINGTON, MA 02421
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
UPB CFO and COO 28,795 $6.01 $173.1K -$13.1K 4 2026-06-17
Enliven Therapeutics, Inc. (IMRA) Delisted CFO & COO 6,902 $14.59 $100.7K -$91.4K 5 2023-02-22
X4 Pharmaceuticals, Inc (ASNS) Delisted President, CEO and CFO 417 $0.08 $32 $0 2 2018-11-28
CRIS CFO 54 $1.35 $73 -$298.4K 18 2015-05-28

Recent Filings

29 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-17 UPB Sell (S) −853 -$5.2K EDGAR
2026-03-17 UPB Sell (S) −852 -$7.9K EDGAR
2026-01-06 UPB Grant (A) +30,500 $0 EDGAR
2025-02-07 UPB Grant (A) — $0 EDGAR
2023-02-22 Enliven Therapeutics, Inc. (IMRA) Delisted Sell (S) −9,856 -$46.0K EDGAR
2023-02-01 Enliven Therapeutics, Inc. (IMRA) Delisted Sell (S) −3,596 -$14.1K EDGAR
2022-02-01 Enliven Therapeutics, Inc. (IMRA) Delisted Grant (A) +39,350 $0 EDGAR
2021-01-28 Enliven Therapeutics, Inc. (IMRA) Delisted Grant (A) — $0 EDGAR
2020-12-15 Enliven Therapeutics, Inc. (IMRA) Delisted Mixed — -$25.1K EDGAR
2018-11-28 X4 Pharmaceuticals, Inc (ASNS) Delisted Grant (A) +250,000 $0 EDGAR
Showing 1–10 of 29
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.